Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2024 Feb 20;22(1):25.
doi: 10.1186/s12958-024-01196-9.

Evaluation of serum adiponectin as a marker of insulin resistance in women with polycystic ovarian syndrome: a comparative cross-sectional study

Olugbenga Ojatokunbo Runsewe  1 , Abiodun Adeniyi Adewunmi  2   3 , Gbenga Olorunfemi  4 , Abimbola Tawaqualit Ottun  5   6 , Ayokunle Moses Olumodeji  5   6 , Babalola Ogungbemile  1 , Tamramat Iyabo Runsewe-Abiodun  7
Affiliations
Comparative Study

Evaluation of serum adiponectin as a marker of insulin resistance in women with polycystic ovarian syndrome: a comparative cross-sectional study

Olugbenga Ojatokunbo Runsewe et al. Reprod Biol Endocrinol. .

Abstract

Background: Insulin resistance (IR) is known to be prevalent amongst women with polycystic ovarian syndrome (PCOS). Its presence has been linked to chronic anovulation and marked long term complications in women. Hence, identification and treatment of IR in women with PCOS is required to prevent the metabolic and reproductive complications of the disease. The aim of this study is to determine if serum adiponectin could be used as a surrogate marker for insulin resistance among women with PCOS.

Materials and methods: A total number of 148 consenting women with PCOS diagnosed using the Rotterdam criteria were recruited for this study. Fifty-two of these women had insulin resistance were compared with 96 of the women who did not have insulin resistance. The serum Adiponectin levels, fasting blood glucose and fasting insulin levels were assayed in all study participants. Insulin resistance was assessed in all the study participants using the Homeostasis Model Assessment for Insulin Resistance (HOMA-IR). Data were analyzed using relevant inferential statistics at 95% confidence interval and p value of < 0.05.

Results: The prevalence of insulin resistance among the study participants was 35.1%. Majority of the women (83.1%) had a high body mass index (BMI). More than half (68.2%) of the participants were in the age range of 21-30years and 76.4% (113) were nulliparous. There was no statistically significant difference in the median adiponectin level among insulin resistant (3.735 ug/ml) and non-insulin resistant participants vs. (3.705 ug/ml) (p = 0.6762). Both univariate and multivariate regression analysis did not show a statistically significant relationship between adiponectin and insulin resistance in PCOS.

Conclusion: The prevalence of insulin resistance in women with PCOS is high and serum adiponectin is not a suitable surrogate marker of insulin resistance in women with PCOS.

Keywords: Adiponectin; Insulin resistance; PCOS.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Box plot of the distribution of Adiponectin levels among insulin and non-insulin resistant participants
See this image and copyright information in PMC

References

    1. Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, et al. Polycystic ovary syndrome. Nat Reviews Disease Primers. 2016;2(1):1–18. - PubMed
    1. Azziz R. Polycystic ovary syndrome. Obstet Gynecol. 2018;132(2):321–36. doi: 10.1097/AOG.0000000000002698. - DOI - PubMed
    1. Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Reviews Endocrinol. 2018;14(5):270–84. doi: 10.1038/nrendo.2018.24. - DOI - PubMed
    1. Guan C, Zahid S, Minhas AS, Ouyang P, Vaught A, Baker VL, et al. Polycystic ovary syndrome: a risk-enhancing factor for cardiovascular disease. Fertil Steril. 2022;117(5):924–35. doi: 10.1016/j.fertnstert.2022.03.009. - DOI - PubMed
    1. Louwers YV, Laven JS. Characteristics of polycystic ovary syndrome throughout life. Therapeutic Adv Reproductive Health. 2020;14:2633494120911038. doi: 10.1177/2633494120911038. - DOI - PMC - PubMed

Publication types